Fig. 2

TME correction in EWAS identifies 2093 tumor-specific CpGs when comparing tumor versus non-tumor groups. Epigenome-wide association study of prostate cancer and matched non-tumor normal prostate tissue adjusted for patient age, race, Gleason score, pathological stage, and preoperative PSA levels, immune and angiogenic cell-type proportions from HiTIMED hierarchical level two, and blocked on patient ID. Each point represents a CpG site; in total, 746,980 CpG sites are shown, and those with an FDR Q-value < 0.05 are shown in red (2093 CpGs). FDR Q-value < 0.05 is shown above the blue line, and FDR Q-value < 0.01 is shown above the red line